Mouse Monoclonal GRM5 Antibody

The GRM5 antibody targets the metabotropic glutamate receptor 5 (mGluR5), a class C G protein-coupled receptor (GPCR) primarily expressed in the central nervous system (CNS). mGluR5 regulates synaptic transmission, plasticity, and excitatory signaling by modulating intracellular pathways via coupling with Gαq proteins. It plays critical roles in learning, memory, and neurodevelopment, and is implicated in neurological disorders such as Fragile X syndrome, autism, schizophrenia, and Parkinson’s disease. GRM5 antibodies are essential tools for studying receptor localization, expression levels, and function in normal and diseased tissues. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate mGluR5’s role in synaptic regulation and its interactions with ligands or allosteric modulators. Additionally, these antibodies aid in drug discovery, particularly for mGluR5-targeted therapies aiming to treat cognitive deficits or neuropsychiatric conditions. Recent research also explores mGluR5’s involvement in cancer, such as melanoma and glioma, highlighting the antibody’s utility in oncology. Validated GRM5 antibodies exhibit specificity across human, rodent, and other model species, supporting translational studies. Proper validation via knockout controls ensures reliability in distinguishing mGluR5 from related receptors (e.g., mGluR1), minimizing cross-reactivity. Overall, GRM5 antibodies are pivotal in advancing neuroscience, pharmacology, and oncology research.